Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Más filtros

Bases de datos
Tipo del documento
Intervalo de año de publicación
1.
Exp Dermatol ; 22(3): 210-5, 2013 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-23489424

RESUMEN

The beneficial effects of certain herbal medicines on cutaneous function have been appreciated for centuries. Among these agents, chrysanthemum extract, apigenin, has been used for skin care, particularly in China, for millennia. However, the underlying mechanisms by which apigenin benefits the skin are not known. In this study, we first determined whether topical apigenin positively influences permeability barrier homoeostasis, and then the basis thereof. Hairless mice were treated topically with either 0.1% apigenin or vehicle alone twice daily for 9 days. At the end of the treatments, permeability barrier function was assessed with either an electrolytic water analyzer or a Tewameter. Our results show that topical apigenin significantly enhanced permeability barrier homoeostasis after tape stripping, although basal permeability barrier function remained unchanged. Improved barrier function correlated with enhanced filaggrin expression and lamellar body production, which was paralleled by elevated mRNA levels for the epidermal ABCA12. The mRNA levels for key lipid synthetic enzymes also were upregulated by apigenin. Finally, both cathelicidin-related peptide and mouse beta-defensin 3 immunostaining were increased by apigenin. We conclude that topical apigenin improves epidermal permeability barrier function by stimulating epidermal differentiation, lipid synthesis and secretion, as well as cutaneous antimicrobial peptide production. Apigenin could be useful for the prevention and treatment of skin disorders characterized by permeability barrier dysfunction, associated with reduced filaggrin levels and impaired antimicrobial defenses, such as atopic dermatitis.


Asunto(s)
Apigenina/administración & dosificación , Apigenina/farmacología , Permeabilidad de la Membrana Celular/efectos de los fármacos , Epidermis/fisiología , Homeostasis/efectos de los fármacos , Extractos Vegetales/administración & dosificación , Extractos Vegetales/farmacología , Transportadoras de Casetes de Unión a ATP/metabolismo , Administración Tópica , Animales , Péptidos Catiónicos Antimicrobianos/metabolismo , Diferenciación Celular/efectos de los fármacos , Diferenciación Celular/fisiología , Permeabilidad de la Membrana Celular/fisiología , Células Cultivadas , Chrysanthemum , Relación Dosis-Respuesta a Droga , Células Epidérmicas , Epidermis/efectos de los fármacos , Femenino , Proteínas Filagrina , Homeostasis/fisiología , Proteínas de Filamentos Intermediarios/metabolismo , Queratinocitos/citología , Queratinocitos/efectos de los fármacos , Queratinocitos/metabolismo , Ratones , Ratones Pelados , Modelos Animales , Piel/citología , Piel/efectos de los fármacos , Piel/metabolismo , beta-Defensinas/metabolismo , Catelicidinas
2.
Exp Dermatol ; 22(1): 30-5, 2013 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-23173934

RESUMEN

There is mounting evidence that Th2 cytokines adversely affect skin barrier functions and contribute to the pathogenesis of atopic dermatitis (AD). AD is also characterized by abnormal cohesion in the stratum corneum (SC). However, the contribution of Th2 cytokines to this abnormality remains unknown. This study examined the effects of IL-4, a prototypic Th2 cytokine, on the cohesion of the SC. Structural and physiological assessments revealed that repeated intradermal injections of IL-4 compromised the cohesion of the SC of normal hairless mice. Two potential mechanisms were explored to account for the altered cohesion. First, IL-4 decreased the amount of corneodesmosomes and down-regulated the expression of desmoglein 1, but not of corneodesmosin (CDSN) or loricrin expression, in murine skin and in cultured human keratinocytes (KC). IL-4 did not affect the skin surface pH, and in situ zymography revealed no net change in total serine protease activity in the IL-4-treated SC. Yet, IL-4 enhanced expression of kallikrein (KLK)7, while simultaneously down-regulating KLK5 and KLK14. Finally, IL-4 did not alter the expression of the lympho-epithelial Kazal-type inhibitor (LEKTI) in KC. This study suggests that IL-4 abrogates the cohesion of SC primarily by reducing epidermal differentiation.


Asunto(s)
Adyuvantes Inmunológicos/farmacología , Dermatitis Atópica/etiología , Epidermis/efectos de los fármacos , Epidermis/metabolismo , Interleucina-4/farmacología , Queratinocitos/efectos de los fármacos , Animales , Calcio/farmacología , Diferenciación Celular/efectos de los fármacos , Células Cultivadas , Desmogleína 1/metabolismo , Epidermis/ultraestructura , Femenino , Glicoproteínas/metabolismo , Humanos , Péptidos y Proteínas de Señalización Intercelular , Calicreínas/metabolismo , Queratinocitos/metabolismo , Proteínas de la Membrana/metabolismo , Ratones , Ratones Endogámicos C57BL , Proteínas Inhibidoras de Proteinasas Secretoras/metabolismo , ARN Mensajero/metabolismo , Inhibidor de Serinpeptidasas Tipo Kazal-5 , Serina Proteasas/metabolismo
3.
Exp Dermatol ; 20(3): 285-8, 2011 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-21323748

RESUMEN

Chinese herbal medicine (CHM) has been shown to have beneficial effects for both skin disorders with barrier abnormality and as skin care ingredients. Yet, how CHM exerts their benefits is unclear. As most, if not all, inflammatory dermatoses are accompanied by abnormal permeability barrier function, we assessed the effects of topical CHM extracts on epidermal permeability barrier function and their potential mechanisms. Topical CHM accelerated barrier recovery following acute barrier disruption. Epidermal lipid content and mRNA expression of fatty acid and ceramide synthetic enzymes increased following topical CHM treatment in addition to mRNA levels for the epidermal glucosylceramide transport protein, ATP-binding cassette A12. Likewise, CHM extract increased mRNA expression of antimicrobial peptides both in vivo and in vitro. These results demonstrate that the topical CHM extract enhances epidermal permeability barrier function, suggesting that topical CHM could provide an alternative regimen for the prevention/treatment of inflammatory dermatoses accompanied by barrier abnormalities.


Asunto(s)
Medicamentos Herbarios Chinos/farmacología , Epidermis/efectos de los fármacos , Permeabilidad/efectos de los fármacos , Piel/efectos de los fármacos , Transportadoras de Casetes de Unión a ATP/genética , Amidohidrolasas/genética , Animales , Péptidos Catiónicos Antimicrobianos/genética , Péptidos Catiónicos Antimicrobianos/metabolismo , Medicamentos Herbarios Chinos/aislamiento & purificación , Células Epidérmicas , Epidermis/metabolismo , Femenino , Expresión Génica/efectos de los fármacos , Expresión Génica/genética , Humanos , Queratinocitos/efectos de los fármacos , Queratinocitos/metabolismo , Metabolismo de los Lípidos/efectos de los fármacos , Ratones , Ratones Pelados , Vesículas Secretoras/metabolismo , Serina C-Palmitoiltransferasa/genética , Piel/citología , Piel/metabolismo , Regulación hacia Arriba/genética , beta-Defensinas/genética , beta-Defensinas/metabolismo , Catelicidinas
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA